TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03947216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood analysis
Description: Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac monitoring
Description: Electrocardiogram will be realized at day 0, 28 and 56.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac monitoring
Description: Electrocardiogram will be realized at day 0, 28 and 56.
Study: NCT03064568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 100Mcg Tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04219670

Intervention type: DIAGNOSTIC_TEST
Intervention: Wearable sensors
Description: Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Wearable sensors
Description: Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
Study: NCT03855449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eDECIDE Web-based Intervention Group
Description: Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eDECIDE Web-based Intervention Group
Description: Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention
Study: NCT03817424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Participants will receive VIB7734 via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Participants will receive VIB7734 via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Participants will receive VIB7734 via injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to VIB7734 via injection.
Study: NCT04310995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil 5mg tid
Description: oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem 180mg qd
Description: oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 50mg qd
Description: oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
Study: NCT04064489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRIPscore
Description: TRIPcast score calculation
Study: NCT01446081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
Study: NCT04512521

Intervention type: DRUG
Intervention: Mepolizumab
Description: Mepolizumab therapy
Study: NCT00989768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (Dysport®)
Description: Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A/Botox®
Description: 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A/Dysport®
Description: Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox.
Study: NCT00146575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (Cypher)
Description: patients have been implanted a Cypher stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (Taxus)
Description: patients have been implanted a Taxus stent
Study: NCT02192502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human albumin 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (Voluven)
Study: NCT01196338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early weight-bearing and range of motion exercises
Description: * 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-weight bearing, no range of motion
Description: * 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis.
Study: NCT03550092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstract Semantic Association Network Training (AbSANT)
Description: In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
Study: NCT00471081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One or 2 intramuscular injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One or 2 intramuscular injections.
Study: NCT01863199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis (Treat and extend)
Description: Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis every 4 weeks
Description: Lucentis 0.5mg administered intravitreally every four weeks for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis every 12 weeks
Description: Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
Study: NCT04652531

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Autologous extracellular vesicles from serum
Description: Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous extracellular vesicles from serum
Description: Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.
Study: NCT05724680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: Psycho-therapeutic intervention
Study: NCT03441750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin tablets will be administrated in the experimental arm.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard lifestyle intervention
Description: Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid.
Study: NCT00705042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study: NCT05724680

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive behavior therapy
Description: Psycho-therapeutic intervention
Study: NCT02906501

Intervention type: PROCEDURE
Intervention: The Penn Web-Based Computerized Neurocognitive Battery
Description: The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
Study: NCT03054792

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Oxygen Level Dependent [BOLD] MRI
Description: BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diffusion-Weighted [DW] MRI
Description: DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy [MRS]
Description: MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
Study: NCT01270347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin Solution for Inhalation)
Description: MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIS (Tobramycin Inhalation Solution)
Description: Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
Study: NCT03238027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
Study: NCT00481429

Intervention type: DRUG
Intervention: Rosiglitazone
Description: Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
Study: NCT03681158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
Study: NCT03543930

Intervention type: DEVICE
Intervention: Postoperative preventive CPAP
Description: Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2

Intervention type: DEVICE
Intervention: Postoperative preventive CPAP
Description: Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
Study: NCT01839110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice per day for a total of 26 weeks.
Study: NCT00233077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Assistance
Description: Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information only
Description: Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
Study: NCT02635880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Enlighten Device
Description: Up to 3 laser treatments, spaced 4 to 6 weeks apart
Study: NCT02145546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propafenone
Description: 150mg per 8 hours, 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: 80mg twice per day.
Study: NCT01505023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partial meal replacement
Description: The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partial meal replacement with inulin
Description: The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
Study: NCT03845153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Retard 850 mg
Description: tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet
Study: NCT02765412

Intervention type: OTHER
Intervention: Webinar, Promotion, and Tool Access
Description: All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.

Intervention type: OTHER
Intervention: Webinar, Promotion, and Tool Access
Description: All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
Study: NCT04026074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Weight adapted drug application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Weight adapted drug application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Weight adapted drug application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Salve application on the body part where the regional anaesthesia will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: i.v. administration of 0,9% NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv
Description: i.v. administration of 0,9% NaCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered